CNS Drugs

, Volume 21, Issue 5, pp 429–437 | Cite as

Pramipexole

In Restless Legs Syndrome
Adis Drug Profile

Abstract

▴ Pramipexole is an oral, non-ergoline dopamine agonist with selectivity for the dopamine D3 receptor, which was recently approved in the EU and the US for the treatment of idiopathic restless legs syndrome (RLS) in adults.

▴ In a polysomnographic study, pramipexole 0.125, 0.25, 0.50 or 0.75mg once daily for 3 weeks significantly reduced from baseline the periodic limb movement index compared with placebo (−27 to-53 vs −3).

▴ Pramipexole at a median dosage of 0.35 mg/day for 6 weeks significantly reduced from baseline the mean International RLS Study Group rating scale (IRLS) score compared with placebo (−12.4 vs −6.1) and produced a significantly higher response (‘much improved’ or ‘very much improved’) rate (63% vs 33%) according to the Clinical Global Impressions-Improvement (CGI-I) scale.

▴ In a controlled-withdrawal study in which responders to pramipexole following 6 months’ therapy were randomised to pramipexole or placebo for 12 weeks, significantly less pramipexole than placebo recipients reached the target event of predefined worsening of symptoms (21% vs 86%).

▴ Treatment with pramipexole 0.25, 0.50 or 0.75mg once daily for 12 weeks significantly reduced IRLS scores from baseline values (−13 to −14 vs −9) and produced significantly higher proportions of CGI-I responders (68–75% vs 51%) compared with placebo.

▴ Pramipexole was generally well tolerated, with most adverse events being transient and of mild to moderate severity.

References

  1. 1.
    Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004 May 1; 27(3): 560–83PubMedGoogle Scholar
  2. 2.
    Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003 Mar; 4(2): 101–19PubMedCrossRefGoogle Scholar
  3. 3.
    Allen RP. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007 Jan; 120(1 Suppl. 1): S13–21PubMedCrossRefGoogle Scholar
  4. 4.
    Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006 Oct; 13(10): 1049–65PubMedCrossRefGoogle Scholar
  5. 5.
    Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson’s disease. Drugs Aging 1998 Jun; 12(6): 495–514PubMedCrossRefGoogle Scholar
  6. 6.
    Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol 1998; 21(3): 141–51PubMedGoogle Scholar
  7. 7.
    Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995 Jun 23; 290(1): 29–36PubMedCrossRefGoogle Scholar
  8. 8.
    Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Influence of renal impairment and hemodialysis on pramipexole pharmacokinetics [abstract no. P249]. Mov Disord 1997; 12Suppl. 1: 66Google Scholar
  9. 9.
    Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Influence of probenecid and cimetidine on pramipexole pharmacokinetics [abstract no. PII-99]. Clin Pharmacol Ther 1996 Feb; 59(2): 183CrossRefGoogle Scholar
  10. 10.
    Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Influence of age and gender on pramipexole pharmacokinetics [abstract no. PII-100]. Clin Pharmacol Ther 1996 Feb; 59(2): 184CrossRefGoogle Scholar
  11. 11.
    Wright CE, Lasher Sisson T, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997 Jun; 37(6): 520–5PubMedGoogle Scholar
  12. 12.
    Boehringer Ingelheim International GmbH. Mirapexin (pramipexole dihydrochloride monohydrate): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Jan 25]
  13. 13.
    Boehringer Ingelheim Pharmaceuticals Inc. Mirapex® (pramipexole dihydrochloride): US prescribing information [online]. Available from URL: http://bidocs.boehringeringelheim.com [Accessed 2007 Jan 31]
  14. 14.
    Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study—the PRELUDE study. Sleep Med 2006 Aug; 7(5): 407–17PubMedCrossRefGoogle Scholar
  15. 15.
    Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006 Sep 26; 67(6): 1034–9PubMedCrossRefGoogle Scholar
  16. 16.
    Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. The German RLS-Pramipexole Study Group. Mov Disord 2006 Sep; 21(9): 1404–10Google Scholar
  17. 17.
    Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). The Pramipexole RLS Study Group. Mov Disord 2007 Jan 15; 22(2): 213–9CrossRefGoogle Scholar
  18. 18.
    Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Acute placebocontrolled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002 Aug; 252(4): 185–94PubMedGoogle Scholar
  19. 19.
    Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999 Mar 23; 52(5): 938–43PubMedCrossRefGoogle Scholar
  20. 20.
    Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006 Dec; 13(12): 1306–11PubMedCrossRefGoogle Scholar
  21. 21.
    Emura N, Kuroda K, Inoue Y, et al. Effects of pramipexole on sleep parameters during a randomized, controlled trial in Japanese patients with restless legs syndrome [abstract no. P403]. Mov Disord 2006 Jan; 21Suppl. 15: S438Google Scholar
  22. 22.
    Mathis J, Bassetti C. Comparison of pramipexole versus levodopa/benserazide in the treatment of restless legs syndrome: a double blind, randomized, Swiss multi-centre crossover trial. Swiss RLS Study Group [abstract no. P419]. Mov Disord 2006 Jan; 21Suppl. 15: S442Google Scholar
  23. 23.
    Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. The International Restless Legs Syndrome Study Group. Sleep Med 2003 Mar; 4(2): 121–32Google Scholar
  24. 24.
    Stiasny-Kolster K, Oertel W. Pramipexole-an effective treatment option in restless legs syndrome patients with depressed mood [abstract no. P195]. Mov Disord 2005; 20Suppl. 10: S59. Plus poster presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders; 2005 Mar 5–8; New Orleans (LA)Google Scholar
  25. 25.
    Partinen M, Hirvonen K, Jama L, et al. Sustained efficacy of pramipexole in restless legs syndrome: results from a 6-month extension of a 3-week trial [abstract no. P390]. Mov Disord 2006 Jan; 21Suppl. 15: S434Google Scholar
  26. 26.
    Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Six-month efficacy of pramipexole for restless legs syndrome: results from a 20-week extension of a 6-week study [abstract no. P405]. Mov Disord 2006 Jan; 21Suppl. 15: S438Google Scholar
  27. 27.
    Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Sustained effects of pramipexole on mood in patients with restless legs syndrome [abstract no. P1156]. 10th Congress of the European Federation of Neurological Societies; 2006 Sep 2–5; GlasgowGoogle Scholar
  28. 28.
    Inoue Y, Fujita M, Shimizu T, et al. Efficacy and safety of pramipexole in Japanese patients with restless legs syndrome [abstract no. P418]. Mov Disord 2006 Jan; 21Suppl. 15: S442Google Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations